Skip to main content
OpenTrials
Completed

NCT Number: NCT05727800

A Phase 1, First-in-human Study of VX-668

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alpha-1 Antitrypsin Deficiency Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Emphysema Genetic Diseases, Inborn Liver Diseases Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Subcutaneous Emphysema alpha 1-Antitrypsin Deficiency

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Celerion - Tempe, Tempe, Arizona, United States

Loading trial locations.

About this study

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Participants of age between 18 to 55 years (inclusive)
  • Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)
  • A total body weight of more than (>)50 kg
  • Nonsmoker or ex-smoker for at least 3 months before screening

Key Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • Females of childbearing potential

Other protocol defined Inclusion/Exclusion criteria may apply.

Treatment and study plan

VX-668

Drug

Suspension for oral administration.

Placebo

Drug

Suspension for oral administration.

Primary outcomes

  1. Part A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 20

Secondary outcomes

  1. Part A and B: Maximum Observed Plasma Concentration (Cmax) of VX-668

    Time frame: Day 1 up to Day 20

  2. Part A and B: Area Under the Concentration Versus Time Curve (AUC) of VX-668

    Time frame: Day 1 up to Day 20

  3. Part A and B: Urine Concentration of VX-668

    Time frame: Part A Cohort A3: Days 1 and 5; Part B Cohort B3: Days 1, 10, and 11

Sponsors and collaborators

Lead sponsor

Vertex Pharmaceuticals Incorporated

Industry

Registry information

Official study title

A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Feb 14, 2023
Registry last updated
Mar 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.